CA-HILLSTONE-NETWORKS
24.1.2023 08:01:36 CET | Business Wire | Press release
Hillstone Networks, a leading provider of innovative and accessible cybersecurity solutions, has announced a major upgrade to its operating system, Hillstone StoneOS 5.5R10. The latest upgrade delivers AI-based high performance threat protection, centralized Zero Trust control and management, and further simplification of security operations and system optimization, among over 300 new features. The new functionality enhances the security posture of customer environments and further streamlines security operations with an easy upgrade path.
Threat protection enhancements with AI technology
The new StoneOS leverages AI technology to provide ML-based threat detection for encrypted traffic without the need for decryption. It also features intelligent DDoS protection and DGA detection. In addition, included is a blacklist extension that empowers the Perimeter Traffic Filtering (PTF) function and delivers more protection against threats.
Centralized Zero Trust control and management
Advanced ZTNA implements centralized management for ZTNA policies through Hillstone Security Management (HSM), and supports intelligent connection to ZTNA gateways, single packet authentication (SPA), multiple vendor Operating System support for ZTNA clients, along with a ZTNA portal. The new features provide a better user experience with improved overall operations and management of the ZTNA solution.
Smarter interconnectivity with extended VPN capabilities
The extended VPN features support ECMP and failover for intelligent VPN routing and provide IPSec VPN tunnel establishment options by configuring custom ports and auto-negotiation. These features bring better bandwidth utilization and improve connectivity, ensuring the business remains undisrupted.
Streamlined system operations offload redundant workloads
The latest StoneOS introduces a simplified start-up wizard and automated NAT redundancy check to facilitate system operations, improving overall productivity for organizations by streamlining the workload of system administrators.
Robust system-wide enhancements further ensure business continuity
System availability is improved across the board in the latest release, with support for advanced High Availability (HA) and the graceful restart of Border Gateway Protocol (BGP), further ensuring that business services remain uninterrupted for organizations.
“The transition from the traditional, edge-based security model to the distributed workforce model is a seismic change, triggered primarily by the pandemic-induced work from home mandate, but the impact will evolve gradually, and therefore the solutions we deliver need to address the associated challenges,” states Tim Liu, CTO and co-founder, Hillstone Networks, “The latest iteration of StoneOS continues to address the challenges faced by SecOps teams, and the constant risks faced by enterprises globally. Enhanced AI-driven threat protection, better integration, centralized control and management, and streamlined operations are all critical in delivering a stable and strategic approach to cyber-resilient cybersecurity environments.”
StoneOS is the foundation for all Hillstone next-generation firewalls, which has been recognized in the 2022 Gartner® Magic Quadrant™ for Network Firewalls for the 9th consecutive year as a Visionary. StoneOS 5.5R10 is now generally available.
About Hillstone Networks
Hillstone Networks’ innovative and accessible cybersecurity solutions reshape enterprise security, enabling cyber resilience while lowering TCO. By providing comprehensive visibility, superior intelligence, and rapid protection to see, understand, and act against multilayer, multistage cyber threats, Hillstone is favorably rated by leading analysts and trusted by global companies. To learn more visit www.hillstonenet.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom